keyword
MENU ▼
Read by QxMD icon Read
search

Drug induced dyskinesia

keyword
https://www.readbyqxmd.com/read/29352477/benzodiazepines-for-antipsychotic-induced-tardive-dyskinesia
#1
REVIEW
Hanna Bergman, Paranthaman S Bhoopathi, Karla Soares-Weiser
BACKGROUND: Tardive dyskinesia (TD) is a disfiguring movement disorder, often of the orofacial region, frequently caused by using antipsychotic drugs. A wide range of strategies have been used to help manage TD, and for those who are unable to have their antipsychotic medication stopped or substantially changed, the benzodiazepine group of drugs have been suggested as a useful adjunctive treatment. However, benzodiazepines are very addictive. OBJECTIVES: To determine the effects of benzodiazepines for antipsychotic-induced tardive dyskinesia in people with schizophrenia, schizoaffective disorder, or other chronic mental illnesses...
January 20, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29352351/levodopa-induced-dyskinesia-in-parkinson-s-disease-still-no-proof-a-meta-analysis
#2
Alexandros Giannakis, Maria Chondrogiorgi, Christos Tsironis, Athina Tatsioni, Spiridon Konitsiotis
We investigated whether there is a linear relationship between levodopa (LD) dose and treatment duration, and the development of levodopa-induced dyskinesia (LID) among patients with early untreated Parkinson's disease (PD). We performed a meta-analysis of randomized-controlled trials (RCTs) comparing LD monotherapy to any other antiparkinsonian treatment in early PD patients. Meta-regressions were conducted including as covariates the effects of LD dose, treatment duration, and age. We further proceeded in subgroup analyses based on the type of medications in the non-LD monotherapy (control) group and on whether patients in the control group received additional levodopa or not...
January 19, 2018: Journal of Neural Transmission
https://www.readbyqxmd.com/read/29342497/non-antipsychotic-catecholaminergic-drugs-for-antipsychotic-induced-tardive-dyskinesia
#3
REVIEW
Hany G El-Sayeh, John Rathbone, Karla Soares-Weiser, Hanna Bergman
BACKGROUND: Tardive dyskinesia (TD) is a disabling movement disorder associated with the prolonged use of antipsychotic medication. Several strategies have been examined in the treatment of TD. Currently, however, there is no clear evidence of the effectiveness of these drugs in TD and they have been associated with many side effects. One particular strategy would be to use pharmaceutical agents which are known to influence the catecholaminergic system at various junctures. OBJECTIVES: 1...
January 18, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29341071/anticholinergic-medication-for-antipsychotic-induced-tardive-dyskinesia
#4
REVIEW
Hanna Bergman, Karla Soares-Weiser
BACKGROUND: Antipsychotic (neuroleptic) medication is used extensively to treat people with serious mental illnesses. However, it is associated with a wide range of adverse effects, including movement disorders. Because of this, many people treated with antipsychotic medication also receive anticholinergic drugs in order to reduce some of the associated movement side-effects. However, there is also a suggestion from animal experiments that the chronic administration of anticholinergics could cause tardive dyskinesia...
January 17, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29338466/valbenazine-as-the-first-and-only-approved-treatment-for-adults-with-tardive-dyskinesia
#5
Harini Sarva, Claire Henchcliffe
Valbenazine is a selective VMAT2 inhibitor that the FDA approved in April 2017 for the specific treatment of tardive dyskinesia (TD), a movement disorder commonly caused by dopamine blocking agents. Valbenazine acts to decrease dopamine release, reducing excessive movement found in TD. Areas covered: This drug profile reviews the development of valbenazine and the clinical trials that led to its approval as the first treatment specific to TD. The literature search was performed with the PubMed online database...
January 17, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29324468/switching-antipsychotic-treatment-to-aripiprazole-in-psychotic-patients-with-neuroleptic-induced-tardive-dyskinesia-a-24-week-follow-up-study
#6
Chia-Hsiang Chan, Hung-Yu Chan, Yen-Ching Chen
Aripiprazole is a second-generation antipsychotics, acting as a partial dopamine D2 receptor agonist. Previous studies on aripiprazole for tardive dyskinesia (TD) treatment were limited and inconclusive. This study was aimed to examine the effectiveness of aripiprazole in psychotic patients with a pre-existing TD. This was an open-label 24-week prospective cohort study conducted in a public mental hospital in Northern Taiwan from January 2009 to February 2010.Psychotic patients were cross-titrated of prior antipsychotics with aripiprazole, and the severity of TD was assessed at baseline and at weeks 2, 4, 8, 12, 16, 20, and 24...
January 10, 2018: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29304113/discovery-of-indolylpiperazinylpyrimidines-with-dual-target-profiles-at-adenosine-a2a-and-dopamine-d2-receptors-for-parkinson-s-disease-treatment
#7
Yi-Ming Shao, Xiaohua Ma, Priyankar Paira, Aaron Tan, Deron Raymond Herr, Kah Leong Lim, Chee Hoe Ng, Gopalakrishnan Venkatesan, Karl-Norbert Klotz, Stephanie Federico, Giampiero Spalluto, Siew Lee Cheong, Yu Zong Chen, Giorgia Pastorin
Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive loss of dopaminergic neurons in the substantia nigra of the human brain, leading to depletion of dopamine production. Dopamine replacement therapy remains the mainstay for attenuation of PD symptoms. Nonetheless, the potential benefit of current pharmacotherapies is mostly limited by adverse side effects, such as drug-induced dyskinesia, motor fluctuations and psychosis. Non-dopaminergic receptors, such as human A2A adenosine receptors, have emerged as important therapeutic targets in potentiating therapeutic effects and reducing the unwanted side effects...
2018: PloS One
https://www.readbyqxmd.com/read/29286148/dl%C3%A2-3%C3%A2-n%C3%A2-butylphthalide-reduces-microglial-activation-in-lipopolysaccharide%C3%A2-induced-parkinson-s-disease-model-mice
#8
Yuhua Chen, Mujun Jiang, Li Li, Ming Ye, Meiling Yu, Lina Zhang, Bobo Ge, Wenfang Xu, Daoxiang Wei
As microglial activation is a key factor in the pathogenesis of Parkinson's disease (PD), drugs that target this process may help to prevent or delay the development of PD. The present study investigated the effects of dl‑3‑n‑butylphthalide (NBP) on microglia in a lipopolysaccharide (LPS)-induced PD mouse model. The mice were randomly divided into a blank control group, LPS control group and NBP + LPS treatment group. Mice in the treatment group were given an intragastric infusion of 120 mg/kg NBP daily for 30 days during the establishment of the PD mouse model...
December 20, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29246613/clinical-management-of-tardive-dyskinesia-five-steps-to-success
#9
REVIEW
Leslie Citrome
Tardive dyskinesia (TD) has long been thought to be a generally irreversible consequence of the use of dopamine receptor blocking agents. There is now an opportunity to successfully manage this condition with agents approved by the US Food and Drug Administration. This is important because TD has not been eliminated with the use of second-generation antipsychotics, and the expansion of antipsychotics to treat conditions other than schizophrenia has resulted in millions of additional individuals at risk for developing TD...
December 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29233065/understanding-the-role-of-glycogen-synthase-kinase-3-in-l-dopa-induced-dyskinesia-in-parkinson-s-disease
#10
Hojin Choi, Seong-Ho Koh
Levodopa (L-DOPA) is the most commonly used drug for Parkinson's disease (PD), but its long-term use is associated with various complications, including L-DOPA-induced dyskinesia (LID). Many studies have suggested that L-DOPA neurotoxicity and LID are associated with glycogen synthase kinase-3 (GSK-3) activation. Areas covered: LID is caused by striatal dopamine (DA) denervation in PD and pulsatile L-DOPA treatment. These factors lead to dysregulated DA transmission, abnormal intracellular signaling and transcription factors in striatal neurons, and altered gene expression and plasticity at corticostriatal synapses...
December 15, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29226687/validation-of-a-new-scoring-scale-for-behavioral-assessment-of-l-dopa-induced-dyskinesia-in-the-rat-a-new-tool-for-early-decision-making-in-drug-development
#11
Simon Loiodice, Anne-Sophie Denibaud, Wendy Deffains, Magali Alix, Pierre Montagne, Marine Seffals, Christophe Drieu La Rochelle
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated non-human primate (NHP) has been described as the most translatable model for experimental reproduction of L-dopa-induced dyskinesia (LID). However, from a drug discovery perspective, the risk associated with investment in this type of model is high due to the time and cost. The 6-hydroxydopamine (6-OHDA) rat dyskinesia model is recommended for testing compounds but relies on onerous, and non-standard behavioral rating scales. We sought to develop a simplified and sensitive method aiming at assessing LID in the rat...
December 11, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/29209877/effects-of-fish-and-grape-seed-oils-as-core-of-haloperidol-loaded-nanocapsules-on-oral-dyskinesia-in-rats
#12
Dalila Moter Benvegnú, Katiane Roversi, Raquel Cristine Silva Barcelos, Fabíola Trevizol, Camila Simonetti Pase, Hecson Jesser Segat, Verônica Tironi Dias, Ana Luiza Savian, Bruna Lopes Piccoli, Jaqueline Piccolo, Carlos Severo Dutra-Filho, Tatiana Emanuelli, Cristiane de Bona da Silva, Ruy Carlos Ruver Beck, Marilise Escobar Burger
Haloperidol is a widely used antipsychotic, despite the severe motor side effects associated with its chronic use. This study was carried out to compare oral dyskinesia induced by different formulations of haloperidol-loaded nanocapsules containing caprylic/capric triglycerides, fish oil or grape seed oil (GSO) as core, as well as free haloperidol. Haloperidol-loaded lipid-core nanocapsules formulations were prepared, physicochemical characterized and administered (0.5 mg kg-1-ip) to rats for 28 days. Oral dyskinesia was evaluated acutely and subchronically and after that cell viability and free radical generation in cortex and substantia nigra...
December 5, 2017: Neurochemical Research
https://www.readbyqxmd.com/read/29191560/msbis-a-multi-step-biomedical-informatics-screening-approach-for-identifying-medications-that-mitigate-the-risks-of-metoclopramide-induced-tardive-dyskinesia
#13
Dong Xu, Alexandrea G Ham, Rickey D Tivis, Matthew L Caylor, Aoxiang Tao, Steve T Flynn, Peter J Economen, Hung K Dang, Royal W Johnson, Vaughn L Culbertson
In 2009 the U.S. Food and Drug Administration (FDA) placed a black box warning on metoclopramide (MCP) due to the increased risks and prevalence of tardive dyskinesia (TD). In this study, we developed a multi-step biomedical informatics screening (MSBIS) approach leveraging publicly available bioactivity and drug safety data to identify concomitant drugs that mitigate the risks of MCP-induced TD. MSBIS includes (1) TargetSearch (http://dxulab.org/software) bioinformatics scoring for drug anticholinergic activity using CHEMBL bioactivity data; (2) unadjusted odds ratio (UOR) scoring for indications of TD-mitigating effects using the FDA Adverse Event Reporting System (FAERS); (3) adjusted odds ratio (AOR) re-scoring by removing the effect of cofounding factors (age, gender, reporting year); (4) logistic regression (LR) coefficient scoring for confirming the best TD-mitigating drug candidates...
November 22, 2017: EBioMedicine
https://www.readbyqxmd.com/read/29167476/levodopa-induced-abnormal-involuntary-movements-correlate-with-altered-permeability-of-the-blood-brain-barrier-in-the-basal-ganglia
#14
Renata P Lerner, Veronica Francardo, Koji Fujita, Zisis Bimpisidis, Vincent A Jourdain, Chris C Tang, Stephen L Dewey, Thomas Chaly, M Angela Cenci, David Eidelberg
Chronic levodopa treatment leads to the appearance of dyskinesia in the majority of Parkinson's disease patients. Neurovascular dysregulation in putaminal and pallidal regions is thought to be an underlying feature of this complication of treatment. We used microPET to study unilaterally lesioned 6-hydroxydopamine rats that developed levodopa-induced abnormal involuntary movements (AIMs) after three weeks of drug treatment. Animals were scanned with [15O]-labeled water and [18F]-fluorodeoxyglucose, to map regional cerebral blood flow and glucose metabolism, and with [11C]-isoaminobutyric acid (AIB), to assess blood-brain-barrier (BBB) permeability, following separate injections of levodopa or saline...
November 22, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29115484/lipoic-acid-alleviates-l%C3%A2-dopa%C3%A2-induced-dyskinesia-in-6%C3%A2-ohda-parkinsonian-rats-via-anti%C3%A2-oxidative-stress
#15
Su-Fang Zhang, Cheng-Long Xie, Jing-Ya Lin, Mei-Hua Wang, Xi-Jin Wang, Zhen-Guo Liu
Levodopa (L‑DOPA) is the gold standard for symptomatic treatment of Parkinson's disease (PD); however, long‑term therapy is associated with the emergence of L‑DOPA‑induced dyskinesia (LID). Nigral dopaminergic cell loss determines the degree of drug exposure and time required for the initial onset of LID. Accumulating evidence indicates that α‑lipoic acid (ALA) decreases this nigral dopaminergic cell loss. However, until now, the precise mechanisms of ALA have only been partially understood in LID...
November 6, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29114100/successful-treatment-of-severe-tardive-dyskinesia-with-valbenazine-including-a-patient-s-perspective
#16
Richard C Josiassen, Dawn M Filmyer, Jack Gillean, Syed Sikandar Shah, Tyler E Dietterich, Rita A Shaughnessy
BACKGROUND Tardive dyskinesia (TD) is a chronic involuntary movement disorder frequently induced by dopamine receptor blockers, particularly first-generation antipsychotics. Until recently, management of TD was restricted to lowering the dose of the current medication, switching to another medication, or using off-label treatments with insufficient evidence of efficacy. Valbenazine, a vesicular monoamine transporter-2 (VMAT2) inhibitor, became the first drug to be approved by the FDA specifically for the treatment of TD...
November 8, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29104832/belly-dancer-s-dyskinesia-a-glimpse-of-a-rare-phenomenon
#17
Ashutosh Gupta, Suman Kushwaha
Belly dancer's dyskinesia (BDD) is an extremely rare manifestation consisting of involuntary and repetitive rhythmic movements of the abdominal wall. These movements cannot be voluntarily suppressed but may be influenced by respiratory maneuvers. Investigations such as spinal cord and abdominal imaging usually fail to reveal any local abnormalities to explain the movement disorder. A 23-year-old male presented with sudden onset of undulating movements of the abdominal wall for the last two months after he took domperidone...
July 11, 2017: Curēus
https://www.readbyqxmd.com/read/29100803/the-effects-of-cysteamine-in-a-mouse-model-of-levodopa-induced-dyskinesias
#18
Linda S David, Martine Saint-Pierre, Jérôme Lamontagne-Proulx, Francesca Cicchetti
Levo-dopa (L-DOPA) has shown significant and long-lasting efficacy in the treatment of motor features characteristic of Parkinson's disease (PD). However, the effects tend to wear off at a time typically when side-effects, such as L-DOPA induced dyskinesias (LIDs), start to emerge and for which the treatment options are very limited. In recent years, we have reported on the neuroprotective and neurorestorative properties of the compounds cystamine/cysteamine in ameliorating several aspects of PD. Building on these observations, we set out to further evaluate the benefits of cysteamine on LIDs...
October 31, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/29076470/-unilateral-posteroventral-pallidotomy-in-the-treatment-of-drug-induced-dyskinesia-in-parkinson-s-disease
#19
V M Tyurnikov, D M Nizametdinova, A O Gushcha, E Yu Fedotova, V V Poleshchuk, S L Timerbaeva, A S Sedov
OBJECTIVE: to determine the efficacy of unilateral posteroventral pallidotomy (PVP) in the treatment of drug-induced dyskinesia (DID) in Parkinson's disease (PD). MATERIAL AND METHODS: We analyzed surgical treatment of 14 patients with PD complicated by DID who underwent unilateral PVP at the Research Center of Neurology in the period between 2012 and 2015. The clinical type of DID was mainly represented by peak-dose choreoathetoid dyskinesia, more pronounced in the distal limbs, and predominantly unilateral...
2017: Zhurnal Voprosy Neĭrokhirurgii Imeni N. N. Burdenko
https://www.readbyqxmd.com/read/29075830/presynaptic-dopamine-depletion-determines-the-timing-of-levodopa-induced-dyskinesia-onset-in-parkinson-s-disease
#20
Han Soo Yoo, Seok Jong Chung, Su Jin Chung, Hyojeong Moon, Jung Su Oh, Jae Seung Kim, Jin Yong Hong, Byoung Seok Ye, Young Ho Sohn, Phil Hyu Lee
PURPOSE: Reduced presynaptic dopaminergic activity plays an important role in the development of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD). In this study, we investigated whether dopaminergic function in the nigrostriatal system is associated with the timing of LID onset. METHODS: From among 412 drug-naive PD patients who underwent a dopamine transporter (DAT) PET scan during their baseline evaluation, we enrolled 65 patients who developed LID during a follow-up period of >2 years...
October 26, 2017: European Journal of Nuclear Medicine and Molecular Imaging
keyword
keyword
120417
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"